301 related articles for article (PubMed ID: 33816289)
21. Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target.
Zhang M; Liu J; Xia Q
Exp Hematol Oncol; 2023 Sep; 12(1):84. PubMed ID: 37770953
[TBL] [Abstract][Full Text] [Related]
22. Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese NSCLC patients.
Song P; Yang D; Wang H; Cui X; Si X; Zhang X; Zhang L
Thorac Cancer; 2020 Jun; 11(6):1621-1632. PubMed ID: 32329229
[TBL] [Abstract][Full Text] [Related]
23. Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review.
Gao L; Yang X; Yi C; Zhu H
Front Pharmacol; 2019; 10():1173. PubMed ID: 31680957
[No Abstract] [Full Text] [Related]
24. The Challenge of ICIs Resistance in Solid Tumours: Could Microbiota and Its Diversity Be Our Secret Weapon?
Roberto M; Carconi C; Cerreti M; Schipilliti FM; Botticelli A; Mazzuca F; Marchetti P
Front Immunol; 2021; 12():704942. PubMed ID: 34489956
[TBL] [Abstract][Full Text] [Related]
25. Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer.
Pinato DJ; Howlett S; Ottaviani D; Urus H; Patel A; Mineo T; Brock C; Power D; Hatcher O; Falconer A; Ingle M; Brown A; Gujral D; Partridge S; Sarwar N; Gonzalez M; Bendle M; Lewanski C; Newsom-Davis T; Allara E; Bower M
JAMA Oncol; 2019 Dec; 5(12):1774-1778. PubMed ID: 31513236
[TBL] [Abstract][Full Text] [Related]
26. Microbiota and Lung Cancer. Opportunities and Challenges for Improving Immunotherapy Efficacy.
Ocáriz-Díez M; Cruellas M; Gascón M; Lastra R; Martínez-Lostao L; Ramírez-Labrada A; Paño JR; Sesma A; Torres I; Yubero A; Pardo J; Isla D; Gálvez EM
Front Oncol; 2020; 10():568939. PubMed ID: 33117698
[TBL] [Abstract][Full Text] [Related]
27. Obesity, cancer, and response to immune checkpoint inhibitors: Could the gut microbiota be the mechanistic link?
Delaye M; Rousseau A; Mailly-Giacchetti L; Assoun S; Sokol H; Neuzillet C
Pharmacol Ther; 2023 Jul; 247():108442. PubMed ID: 37210004
[TBL] [Abstract][Full Text] [Related]
28. Cancer immunotherapy resistance: The impact of microbiome-derived short-chain fatty acids and other emerging metabolites.
Hersi F; Elgendy SM; Al Shamma SA; Altell RT; Sadiek O; Omar HA
Life Sci; 2022 Jul; 300():120573. PubMed ID: 35469916
[TBL] [Abstract][Full Text] [Related]
29. The role of the sex hormone-gut microbiome axis in tumor immunotherapy.
Wang L; Tang L; Zhai D; Song M; Li W; Xu S; Jiang S; Meng H; Liang J; Wang Y; Zhang B
Gut Microbes; 2023; 15(1):2185035. PubMed ID: 36880651
[TBL] [Abstract][Full Text] [Related]
30. A Clinical Outcome of the Anti-PD-1 Therapy of Melanoma in Polish Patients Is Mediated by Population-Specific Gut Microbiome Composition.
Pietrzak B; Tomela K; Olejnik-Schmidt A; Galus Ł; Mackiewicz J; Kaczmarek M; Mackiewicz A; Schmidt M
Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358789
[TBL] [Abstract][Full Text] [Related]
31. Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome.
Simpson RC; Shanahan ER; Batten M; Reijers ILM; Read M; Silva IP; Versluis JM; Ribeiro R; Angelatos AS; Tan J; Adhikari C; Menzies AM; Saw RPM; Gonzalez M; Shannon KF; Spillane AJ; Velickovic R; Lazar AJ; Damania AV; Mishra AK; Chelvanambi M; Banerjee A; Ajami NJ; Wargo JA; Macia L; Holmes AJ; Wilmott JS; Blank CU; Scolyer RA; Long GV
Nat Med; 2022 Nov; 28(11):2344-2352. PubMed ID: 36138151
[TBL] [Abstract][Full Text] [Related]
32. The intimate relationship between gut microbiota and cancer immunotherapy.
Elkrief A; Derosa L; Zitvogel L; Kroemer G; Routy B
Gut Microbes; 2019; 10(3):424-428. PubMed ID: 30339501
[TBL] [Abstract][Full Text] [Related]
33. A narrative review from gut to lungs: non-small cell lung cancer and the gastrointestinal microbiome.
Shah H; Ng TL
Transl Lung Cancer Res; 2023 Apr; 12(4):909-926. PubMed ID: 37197624
[TBL] [Abstract][Full Text] [Related]
34. Integrative analysis of gut microbiome and host transcriptomes reveals associations between treatment outcomes and immunotherapy-induced colitis.
Sakurai T; De Velasco MA; Sakai K; Nagai T; Nishiyama H; Hashimoto K; Uemura H; Kawakami H; Nakagawa K; Ogata H; Nishio K; Kudo M
Mol Oncol; 2022 Apr; 16(7):1493-1507. PubMed ID: 34270845
[TBL] [Abstract][Full Text] [Related]
35. Possible Biomarkers for Cancer Immunotherapy.
Otoshi T; Nagano T; Tachihara M; Nishimura Y
Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31277279
[TBL] [Abstract][Full Text] [Related]
36. The Effects of Gum Acacia on the Composition of the Gut Microbiome and Plasma Levels of Short-Chain Fatty Acids in a Rat Model of Chronic Kidney Disease.
Al-Asmakh M; Sohail MU; Al-Jamal O; Shoair BM; Al-Baniali AY; Bouabidi S; Nasr S; Bawadi H
Front Pharmacol; 2020; 11():569402. PubMed ID: 33628167
[TBL] [Abstract][Full Text] [Related]
37. The Crosstalk between Microbiome and Immunotherapeutics: Myth or Reality.
Tojjari A; Abushukair H; Saeed A
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230563
[TBL] [Abstract][Full Text] [Related]
38. The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer.
Naqash AR; Kihn-Alarcón AJ; Stavraka C; Kerrigan K; Maleki Vareki S; Pinato DJ; Puri S
Ann Transl Med; 2021 Jun; 9(12):1034. PubMed ID: 34277834
[TBL] [Abstract][Full Text] [Related]
39. Gut microbiome and response to checkpoint inhibitors in non-small cell lung cancer-A review.
Nagasaka M; Sexton R; Alhasan R; Rahman S; Azmi AS; Sukari A
Crit Rev Oncol Hematol; 2020 Jan; 145():102841. PubMed ID: 31884204
[TBL] [Abstract][Full Text] [Related]
40. The Core Gut Microbiome of the American Cockroach, Periplaneta americana, Is Stable and Resilient to Dietary Shifts.
Tinker KA; Ottesen EA
Appl Environ Microbiol; 2016 Nov; 82(22):6603-6610. PubMed ID: 27590811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
